{"ticker": {"uuid": "d410570c-d520-402b-97a5-d25a88803071", "symbol": "XENE", "name": "Xenon Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds", "summary": "Xenon Pharmaceuticals (XENE) is attracting investor attention due to its recent stock performance and late-stage epilepsy program. While a common valuation narrative suggests the company is 14.4% undervalued based on aggressive growth projections and future earnings, this hinges ", "url": "https://www.sahmcapital.com/news/content/xenon-pharmaceuticals-xene-could-be-14-undervalued-if-its-epilepsy-narrative-holds-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T13:45:32", "published_display": "14 Jul 2026 13:45", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of Xenon Pharmaceuticals Inc. \u2013 BIVA:XENE/N", "summary": "This article provides the \"Price to sales forward\" for Xenon Pharmaceuticals Inc. (BIVA:XENE/N) as listed on TradingView. It appears to be a financial data snippet rather than a news article, focusing specifically on this one metric for the company. The page indicates no trades w", "url": "https://www.tradingview.com/symbols/BIVA-XENE/N/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T06:12:28", "published_display": "13 Jul 2026 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (XENE) and Scalable Risk", "summary": "Xenon Pharmaceuticals Inc. (XENE) shows strong sentiment across all horizons, supporting an overweight bias with compelling upside potential due to no resistance levels remaining above the current price. AI models have generated three distinct trading strategies\u2014Position Trading,", "url": "https://news.stocktradersdaily.com/news_release/134/Understanding_the_Setup:_XENE_and_Scalable_Risk_071026104601_1783737961.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T22:46:00", "published_display": "10 Jul 2026 22:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals stock hits all-time high at 63.96 USD", "summary": "Xenon Pharmaceuticals Inc. (XENE) recently saw its stock price reach an all-time high of $63.96, surpassing its 52-week high and reflecting a 1-year gain of over 102%. This strong performance comes despite reporting zero revenue in Q1 2026, though EPS exceeded forecasts. Analysts", "url": "https://www.investing.com/news/company-news/xenon-pharmaceuticals-stock-hits-alltime-high-at-6396-usd-93CH-4779806", "source_name": "Investing.com", "published_at": "2026-07-07T17:41:27", "published_display": "07 Jul 2026 17:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Xenon Pharmaceuticals Inc. \u2013 NASDAQ:XENE", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). Although the provided content is largely navigational and informational about the TradingView platform, it specifically highlights this financial ratio within t", "url": "https://www.tradingview.com/symbols/NASDAQ-XENE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T00:42:17", "published_display": "05 Jul 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Xenon Pharmaceuticals Inc. \u2013 NASDAQ:XENE", "summary": "This article displays the \"Price to book forward\" for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). The content is primarily a data point with no further analysis or discussion. It indicates the latest value for this financial metric for the specified company.", "url": "https://www.tradingview.com/symbols/NASDAQ-XENE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T00:40:59", "published_display": "05 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate", "summary": "Xenon Pharmaceuticals (NASDAQ:XENE) has a cash runway of 3.6 years based on its US$1.1 billion cash reserves in March 2026 and a US$307 million cash burn rate. While its cash burn increased by 54% last year, analysts project the company will break even within approximately four y", "url": "https://www.moomoo.com/news/post/72462430/we-re-not-very-worried-about-xenon-pharmaceuticals-nasdaq-xene", "source_name": "Moomoo", "published_at": "2026-07-04T09:40:59", "published_display": "04 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XENE - Xenon Pharmaceuticals Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Xenon Pharmaceuticals Inc. (XENE), including its latest stock performance, key financial metrics, volatility indicators, and analyst recommendations. It highlights the company's market capitalization, income, sales, and vario", "url": "https://finviz.com/stock?t=XENE&p=m&ty=ocv&b=2&r=max&ov=chain_strike&s=45", "source_name": "Finviz", "published_at": "2026-07-04T01:11:01", "published_display": "04 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, consisting of 20,200 share options and 11,850 restricted share units (RSUs). These grants were approved by the Compensation Committee and are material inducements for employment, in c", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321547/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T09:40:59", "published_display": "03 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Xenon Pharmaceuticals Inc. \u2013 NASDAQ:XENE", "summary": "The article focuses on the \"Price to earnings forward\" financial metric for Xenon Pharmaceuticals Inc. (NASDAQ: XENE) as presented on the TradingView platform. It provides the company's stock symbol and market information, indicating that the market was closed at the time the dat", "url": "https://www.tradingview.com/symbols/NASDAQ-XENE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T01:41:05", "published_display": "03 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon awards new hires 20,200 options and 11,850 RSUs", "summary": "Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has granted equity inducement awards to four new non-officer employees, consisting of 20,200 share options and 11,850 restricted share units (RSUs). These grants, approved by the Compensation Committee, have an exercise price of $60.30 an", "url": "https://www.stocktitan.net/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-1o74lq4e7dsn.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:04:00", "published_display": "02 Jul 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XENE - Xenon Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Xenon Pharmaceuticals Inc. (XENE). It includes key financial metrics, performance indicators, insider/institutional ownership details, and analyst recommendations, offering a detailed snapshot of th", "url": "https://finviz.com/stock?t=XENE&p=m&ty=lf&b=2&r=max&page=8", "source_name": "Finviz", "published_at": "2026-07-02T05:41:00", "published_display": "02 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Xenon Pharmaceuticals Inc. \u2013 NASDAQ:XENE", "summary": "This article focuses on the enterprise value to EBIT forward for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). It appears to be a financial data point or a report generated by TradingView, a financial platform. The content primarily lists navigation and footer information related to", "url": "https://www.tradingview.com/symbols/NASDAQ-XENE/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T12:10:27", "published_display": "01 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (XENE) That Institutions Follow", "summary": "This article analyzes Xenon Pharmaceuticals Inc. (NASDAQ: XENE) using AI models to identify institutional trading signals. It highlights strong sentiment across all horizons, an exceptional risk-reward setup, and provides three distinct trading strategies: a Position Trading Stra", "url": "https://news.stocktradersdaily.com/news_release/141/The_Technical_Signals_Behind_XENE_That_Institutions_Follow_062926093801_1782783481.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T21:38:00", "published_display": "29 Jun 2026 21:38", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Positive X-TOLE2 Epilepsy Data And 2026 FDA Filing Plan Altering The Investment Case For Xenon Pharmaceuticals (XENE)?", "summary": "Xenon Pharmaceuticals recently announced positive Phase III X-TOLE2 results for azetukalner in focal onset seizures and plans to submit a new drug application to the FDA for this indication in Q3 2026. This progress advances azetukalner within the company's neuroscience pipeline ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/is-positive-x-tole2-epilepsy-data-and-2026-fda-filing-plan-a/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-24T13:41:15", "published_display": "24 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why", "summary": "Xenon Pharmaceuticals (XENE) stock has surged 22% over the past six months, outperforming the industry's decline, driven by strong investor confidence in its neuroscience pipeline. Key to this growth is azetukalner, the company's lead asset, which showed positive phase III result", "url": "https://finance.yahoo.com/markets/stocks/articles/xenon-pharmaceuticals-stock-gains-22-145900961.html", "source_name": "Market source", "published_at": "2026-06-23T17:11:13", "published_display": "23 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals (XENE) Q4 2025 earnings summary", "summary": "Xenon Pharmaceuticals released its Q4 2025 earnings, highlighting significant progress in Phase 3 clinical trials for azetukalner in epilepsy and neuropsychiatry, with NDA submission expected in 2026. The company expanded its early-stage pipeline and raised $242.2 million through", "url": "https://quartr.com/events/xenon-pharmaceuticals-xene-q4-2025_oqhcq8m4", "source_name": "Quartr", "published_at": "2026-06-23T04:40:32", "published_display": "23 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc (XENE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for Xenon Pharmaceuticals Inc (XENE), including its stock performance, market capitalization, and financial overview. It notes that relevant data regarding business segments, regional revenue, and profit contribution for recent fiscal year", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xene/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:24", "published_display": "18 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc (XENE) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Xenon Pharmaceuticals Inc (XENE), including its major shareholders and institutional holdings. It lists the top individual shareholders like Fidelity Management & Research Company LLC and Avoro Capital Advisors LLC, as well as cat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xene/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:24", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc (XENE) Institutional Confidence", "summary": "Xenon Pharmaceuticals Inc (XENE) has an institutional confidence score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 116.66%, a 21.96% increase quarter-over-quarter. Paul Tudor Jones is the largest institution", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xene/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T08:41:26", "published_display": "17 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc (XENE) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Xenon Pharmaceuticals Inc (XENE), highlighting its current earnings forecast score, analyst ratings, and price targets. It includes a peer comparison and addresses frequently asked questions regarding expected revenue, price targets,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xene/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T08:41:25", "published_display": "17 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate", "summary": "Xenon Pharmaceuticals (XENE) recently experienced a share price pullback, with the stock down around 3% in the past day and 4% in the last week, yet it has shown strong performance over the past year. Despite the recent dip, Simply Wall St assesses XENE as modestly undervalued at", "url": "https://sg.finance.yahoo.com/news/assessing-xenon-pharmaceuticals-xene-valuation-171159398.html", "source_name": "Market source", "published_at": "2026-06-11T17:39:02", "published_display": "11 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE", "summary": "Fiera Capital Corp increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 31.9% in the fourth quarter, bringing its total holdings to 686,056 shares valued at $30.7 million. Several other institutional investors also increased their positions, indicating significant i", "url": "https://www.marketbeat.com/instant-alerts/filing-fiera-capital-corp-boosts-stock-position-in-xenon-pharmaceuticals-inc-xene-2026-06-09/", "source_name": "MarketBeat", "published_at": "2026-06-09T23:39:02", "published_display": "09 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade", "summary": "Xenon Pharmaceuticals director Gary Patou sold 1,322 shares of XENE stock at $53.14 per share on June 5, 2026. This transaction was conducted under a pre-planned Rule 10b5-1 trading plan adopted in August 2025, specifically to cover income tax obligations from the vesting of rest", "url": "https://www.stocktitan.net/sec-filings/XENE/form-4-xenon-pharmaceuticals-inc-insider-trading-activity-65e1bc7cd4e9.html", "source_name": "Stock Titan", "published_at": "2026-06-09T01:39:02", "published_display": "09 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals (XENE) director Cannon sells 1,190 shares under 10b5-1 tax plan", "summary": "Xenon Pharmaceuticals Inc. director Gillian Cannon sold 1,190 common shares at an average price of $53.14 per share on June 5, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, primarily to cover income tax obligations from", "url": "https://www.stocktitan.net/sec-filings/XENE/form-4-xenon-pharmaceuticals-inc-insider-trading-activity-1157e4216298.html", "source_name": "Stock Titan", "published_at": "2026-06-09T01:39:02", "published_display": "09 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Xenon Pharmaceuticals Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Xenon Pharmaceuticals Inc. (XENE), detailing a proposed sale of 1,322 common shares by an insider. The filing indicates the securities were acquired on May 31, 2026, as Restricted Stock Units from the issuer. The aggregated market ", "url": "https://www.stocktitan.net/sec-filings/XENE/144-xenon-pharmaceuticals-inc-sec-filing-cd3da1332bcf.html", "source_name": "Stock Titan", "published_at": "2026-06-07T12:39:44", "published_display": "07 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Xenon Pharmaceuticals (XENE) Valuation After A Recent Pullback And Strong Multi Year Returns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc. Rings the Nasdaq Stock Market Opening Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOZ29fd3dUUFdEZHg2Yk8xTi11SlBoeWItTTQtYWpwSV96dVJfZzNERDEyaDBWMHNra1hsZmd5ZWtIMm0wWE53Nk1KVzhJNmhfZjBDalhQWW4zLV93NDI3aS1KU094S1RLT3ZabmJIUXFCbDE5c0J1Z2tzMVBWMEl3UUpjcXpndWJwaUt3aXpDbXhXSkptOVZFSll3?oc=5", "source_name": "Nasdaq", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOaEpJcU5wUXFpM0Q4RHJVWnRIWTdacjFUd1JqbU14clloakhGUUN2SXdUTXdoUmJtVjJFNVNSV2hVRXE1azAwWUQ0QmNQTHJ3OWJKenNSUTFBTzZLZVNPMmtPTnZCY2N2M2JBZ3lzSjZVX2M4VkhnYm94dE54NVFHaDNwSWhOMmVwTE50MkVrWG5FVDNOZV9QT2UzdTVZdEl3?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This Fund\u2019s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPQUFrTnM0c0MxSHNXYm9RUHBwMVpYNzlMdzJ4Q1NoM003c1MzeDFQWVh0UGpwZHdOSTlqbGxLcjl3ZUFWdVcycmdvRDc3aUFMYk1XazBSNEs0ZnRDamVRODEzajlVZ2pGVXdZdWZ4em16cHlPb0VaT0FQNkNZWFdTeHNFUG1aLWloRkowdGpTdW1sUUdQc0ZrcENzTGdtV2ZlTGticUJPa1VnR2xTVzJYeS1qZ2VpTE1jM1V1NHY3TEVycnJ3TDM1YkZFREhIbzhOcF95S1VaMjR1S1NXZ1pPMQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOV0E1T0hTcGZEMHZ4RVM0Smx2Z3Jic2xaS1YzcWVSNGh1Vll0ckMyaDB4YUFpcnRQeTQwWDlkTHRKMHp5T1hLeHNYSG1XbHF2RXJjUVlGVmlLU3ZUZ3U3c0xDTDhYaHlvZlc4ekY2cjJ1aE9FejY4MWxRZ2twenFrTmNNYVBvMDk4d09QVzFwV3FzTUY5?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOcWJGU3RuSkViYm1wVW8yV3NfaHBWa214X0MwRDRRVDBlRTFUbkgyemYzakdZZVQzM0tTdWJIVjhOYm1OaVJGR1FNZGxBV3JTR1RPQno1LWkwX1FGbFRvSVFKaUJzTGQyQlN1OGQ3dEcwdklFMGttRlp6bHgxenV1U0huaDUzbmNMdkQ1dkdCMXNHZGxpMXhkanZuUkRocUVPTVE0RjY4SWtaNnAwaDBn?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xenon Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNZWxCSGkwTjRJQUttYVVmeGdsRDBOanozWl9LZWxqQTR0VHlzLVBNVEZjWkxVMXFrTVpPNkpWTjQ2NWlYTnRMODZGWXNvX0tEcWp2cDdNaUtjZ0RzbU8xMFBya1hFa1ZZNUhvS0hmc2gxVFhsVzFPWlY2c0FhMllpTWRSdjU0T0thclBjZzlJYTA2UzF4VW5NUzNvVXpUa08zUlktSXFrMXVQOXRqNkFxcDFmTG1ORmpEUWJ1UFNuWkZtOGd2N2I5bXdiN2R4Vm8?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Xenon Pharmaceuticals (XENE) After A 58% One-Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nearly 40% stayed seizure-free for a year in Xenon\u2019s 48-month study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPckRHRjZqWlBJZGw2Mms3eTA3QTFTUXczUlZ6d3Y2R2d3SjVia25Pb09ZLXQ1VnN4OUpxamFCYTMtem56Q29DY3B5aVRoTGlpVjBPQk10SS1yYjBPZi1YdmkwcFlQOTRTWmhBSkFRdzNxT0Q2dDcxT0V6WVpTcTZpM2ZJM055eThQSmdBQlRFUHA1LUg3am91MXRNWkdCSnpSbDM2ZnpkRm40NGxHbkFackhXRGdieTNyU2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon lines up four investor conference presentations in Q2 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQNDNvNDNxMFNjT0s1bWo4TWZtdWY1aWNFdjNRYUo3a2NaUnNieEdPWTBoUF9JX1pFdjhMYzJBeXpZZVhENmxwak1ISGlKM3lEcFlNcXlRdFpOc2xweGtwdmY2NTlpM0xPbGRsVjNUOVVYUFdqWC1ra2xsaGRmZ1R0RE9nbXd5bmdEaEI4T0NVdHY2akVfOEh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPalF4RnBqQlU5MEp5MWtma21jdnN5ZFJNZ0tMUmtScTF6VEtDXzJGQ0kxbHdNT1dmSHlNczlnMHoyVjNSV2hGMWNPMjVqbF84cktDcnJPRElmdVluQXdaQkZqOU4yekhqRmlmVFZUeVBVMHJjZExHVUY1aEJmamtlTnhiT1ZGeGl3bVlpekNWckxJcmt5NF9jUmVGQk15S0ZlbUtLMGNqZWktaGY1NlY3Y2VVa1ZUNGY1eDFodmhURUVHNzNKMFNucXdkNEMybVZOM2VKM2VWTFpDUQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNM3o0VWhQY2FBaWtuMWFlTU9aZmc3alB2VWU5S0ZnZGx5UFFMRXhUYzZpVnRkV28zeGJYcVRNQWk4RU9sNllCMmk0ZktyNkstcEpWNTFSNUhmVkhsRlFzODhTY0xHY0F2bXc1S1UxQlZFWTgxUnpGamNnbEJaeTZEdUhqMVRmYXlNeXBlY1d2ZFdsRHlUaGlLTHVKTXR4NFZjcUM4?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals (XENE) Is Down 6.7% After $650 Million Follow-On Offering And Phase 3 Epilepsy Win", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOSFpmdkYzaWotWGJMb0lleVVGY0lZOVRpMlhPbFc3RGdUTmpOYzF4czBqcmxkc1VvZUNCUFFqX0ZfTjM3WllwNWE0ZjEtb2ZoWXhPY0pONUhUWE8yZlFYVkU4ODFGWWhMbG1paHprZVJxazVzSnhualFZNlJobDZhMXBWeTJreUh1UU01TVJiZXNyWm00NWVZTktxSWRwR2M?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Do Recent Insider Sales at Xenon Pharmaceuticals Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNR3VQZlVLYk1rNi1fZWcyZDQ0ZlBZWjRtLW5KbFYtMFl4NmhzZ1lXZlgyMFd4YlZfOW1ycHFwZTBpTUZaOXpGeVNmTzU2SUhPZ2p2bVp0S0tMMWNTWFNqMkJwVm1KM1lZLTd3SUp2S1pQbmwyQ3FWd1JsX1EteUZiSUt1Y0VzbDE5SkNFMW9oeC13cnhZMFFZbXdINA?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc. Prices Upsized Public Offering, Anticipated Gross Proceeds of Approximately $650 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQYl9MbVRILVlFaUNGSmY2M2JTd3BXVkZ6dmYzN1Q1VzNxWWFFUzM0cmJqN1pWYlp6YndmekJlMy1peXo5aWd6amhjOHlXdkdwYXhzY1pmNGotUmRqRVNVT2JMV0tqQXpVaXVVTVVqM1IzVGxJbTVCb2hYTXY5X2dnSXlCYjh1dmRMNWxuT2F0QlVsbHVMempFclItLVpQMV9OSlFicDZ0M2hfMmZHZDM2aWRIUFBLVVY1R240cnp0VGJWSlJZUmpvVjRXV0JLVkZ1OHUyVlViVTZpam1QcmlsUDBkMVdCeTg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Xenon raises $650M in stock sale at $57 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOWjFPVUI3R1pOSWMxUHM4aHRvUUZkV3U5b05UbHZSZ3ljdGNjNjBxYXhiQklNTHlKM3FfMEN6dGRmMUJOT2R2UlJYTFZRZTZLOC1YT2xzOWNDWEdzZ0tEWkxTN3NFTktSV19oTHRLVFlTTnVSSWs0cXlOQk1QekVzSmg0LVhvNnZ0bzd0LVVmbDRwX2M0a2hrMHUydEhGcWY2bHVWbFVMeGp0eUpkX1A4SXJMZjVRbmpORTVJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals surges 43.6% as Phase 3 azetukalner epilepsy data beats expectations | XENE Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPTW8zQkt6RXBZcUVNZEc1SVRVUkFxV3FKeVU0eldZVzFJMS1WQ0I1UGJ6a2wzcUFTV05Ubmx5V2d6UlBWQk1UV0tDTzVzVWdWMEZyNlZUWV9ZU0xDcnFhTlJDTWJDeURxVlpFTEFZZHU5MnlCOExFUFZUN2V1eXZDZHEwd00tUGRSU1AyY2tlY0VGT1gzVFJ5cFAxUGU5TE1HM1JxNVEzVlJXdUc4Y1BCZkxvOXpWaENfSDQ4RHNuQnp2UjQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals stock surges 40% on positive trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNcDhRNkNoQlAxcEZWRWhIOHJJNFU5UjVPQUFZREdVdjhKYi1WSmprakZlOEFjYjRTQVRoU04xVmtqUnFTU0dmRFp5cElBbDV0Q091QzFvLVE5MktCMVFORWFRaVRlcWxJVE4yRmp2SHVBOWZObVU2UTFVc1dNUFh4UDBPNno3R1RobFdkSjBpbFVjTEI4ZFdmVVRxQ0VaN3lYTVdmSG1OVXgxRnFrbUItTi1TMW9QN1VsOG9hZjRWQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: Chevron, Hims and Hers, Xenon Pharma, Vertiv and more", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPMmZWSnNMTWNIU2RQZXBTY1NyV0J2TFVHaUJQWjhMdHVUZXNnTVFMNTNPdXV1Z0JVU0hLejUxcWlwWmpBbEFBQXY4aGdlaFNnY1N0ZHBSZUZSWVVhM21wMThCRW40bkU3dGZPdV9LSXJMMzh1ZDB3WmFSS2NSaUVNZnlEdnFKY2ZhS2JuN3IzQXV2bE9hWVJPZ1lrZ2ZIZGJU?oc=5", "source_name": "CNBC", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdWFjSms4YllueTRzeGVIUnM5anp4N0dDNVRJbU9aSTFNb21uVEpTc19jRTJyYTRrLVVPNXNfcGwzdTlfWTBtV3c3SUFncFZraXpwX3FaSU9pTi1QdFB4VktTeWlab1MzTnBpeGFaNVgzYktSR05hUHFQeHI5dWtkS2JpY1Zob3VyeEYwMXlmdXlwUkpMenlhaE9CVGRDaWd5eC02TWQ2cXVNWU85bHR6SS1ENXFUYjJmLTZz?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds", "summary": "Xenon Pharmaceuticals (XENE) is attracting investor attention due to its recent stock performance and late-stage epilepsy program. While a common valuation narrative suggests the company is 14.4% undervalued based on aggressive growth projections and future earnings, this hinges ", "url": "https://www.sahmcapital.com/news/content/xenon-pharmaceuticals-xene-could-be-14-undervalued-if-its-epilepsy-narrative-holds-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T13:45:32", "published_display": "14 Jul 2026 13:45", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xenon Pharmaceuticals Inc. \u2013 BIVA:XENE/N", "summary": "This article provides the \"Price to sales forward\" for Xenon Pharmaceuticals Inc. (BIVA:XENE/N) as listed on TradingView. It appears to be a financial data snippet rather than a news article, focusing specifically on this one metric for the company. The page indicates no trades w", "url": "https://www.tradingview.com/symbols/BIVA-XENE/N/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T06:12:28", "published_display": "13 Jul 2026 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (XENE) and Scalable Risk", "summary": "Xenon Pharmaceuticals Inc. (XENE) shows strong sentiment across all horizons, supporting an overweight bias with compelling upside potential due to no resistance levels remaining above the current price. AI models have generated three distinct trading strategies\u2014Position Trading,", "url": "https://news.stocktradersdaily.com/news_release/134/Understanding_the_Setup:_XENE_and_Scalable_Risk_071026104601_1783737961.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T22:46:00", "published_display": "10 Jul 2026 22:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals stock hits all-time high at 63.96 USD", "summary": "Xenon Pharmaceuticals Inc. (XENE) recently saw its stock price reach an all-time high of $63.96, surpassing its 52-week high and reflecting a 1-year gain of over 102%. This strong performance comes despite reporting zero revenue in Q1 2026, though EPS exceeded forecasts. Analysts", "url": "https://www.investing.com/news/company-news/xenon-pharmaceuticals-stock-hits-alltime-high-at-6396-usd-93CH-4779806", "source_name": "Investing.com", "published_at": "2026-07-07T17:41:27", "published_display": "07 Jul 2026 17:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Xenon Pharmaceuticals Inc. \u2013 NASDAQ:XENE", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). Although the provided content is largely navigational and informational about the TradingView platform, it specifically highlights this financial ratio within t", "url": "https://www.tradingview.com/symbols/NASDAQ-XENE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T00:42:17", "published_display": "05 Jul 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Xenon Pharmaceuticals Inc. \u2013 NASDAQ:XENE", "summary": "This article displays the \"Price to book forward\" for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). The content is primarily a data point with no further analysis or discussion. It indicates the latest value for this financial metric for the specified company.", "url": "https://www.tradingview.com/symbols/NASDAQ-XENE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T00:40:59", "published_display": "05 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate", "summary": "Xenon Pharmaceuticals (NASDAQ:XENE) has a cash runway of 3.6 years based on its US$1.1 billion cash reserves in March 2026 and a US$307 million cash burn rate. While its cash burn increased by 54% last year, analysts project the company will break even within approximately four y", "url": "https://www.moomoo.com/news/post/72462430/we-re-not-very-worried-about-xenon-pharmaceuticals-nasdaq-xene", "source_name": "Moomoo", "published_at": "2026-07-04T09:40:59", "published_display": "04 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XENE - Xenon Pharmaceuticals Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Xenon Pharmaceuticals Inc. (XENE), including its latest stock performance, key financial metrics, volatility indicators, and analyst recommendations. It highlights the company's market capitalization, income, sales, and vario", "url": "https://finviz.com/stock?t=XENE&p=m&ty=ocv&b=2&r=max&ov=chain_strike&s=45", "source_name": "Finviz", "published_at": "2026-07-04T01:11:01", "published_display": "04 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, consisting of 20,200 share options and 11,850 restricted share units (RSUs). These grants were approved by the Compensation Committee and are material inducements for employment, in c", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321547/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T09:40:59", "published_display": "03 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Xenon Pharmaceuticals Inc. \u2013 NASDAQ:XENE", "summary": "The article focuses on the \"Price to earnings forward\" financial metric for Xenon Pharmaceuticals Inc. (NASDAQ: XENE) as presented on the TradingView platform. It provides the company's stock symbol and market information, indicating that the market was closed at the time the dat", "url": "https://www.tradingview.com/symbols/NASDAQ-XENE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T01:41:05", "published_display": "03 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon awards new hires 20,200 options and 11,850 RSUs", "summary": "Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has granted equity inducement awards to four new non-officer employees, consisting of 20,200 share options and 11,850 restricted share units (RSUs). These grants, approved by the Compensation Committee, have an exercise price of $60.30 an", "url": "https://www.stocktitan.net/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-1o74lq4e7dsn.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:04:00", "published_display": "02 Jul 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XENE - Xenon Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Xenon Pharmaceuticals Inc. (XENE). It includes key financial metrics, performance indicators, insider/institutional ownership details, and analyst recommendations, offering a detailed snapshot of th", "url": "https://finviz.com/stock?t=XENE&p=m&ty=lf&b=2&r=max&page=8", "source_name": "Finviz", "published_at": "2026-07-02T05:41:00", "published_display": "02 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Xenon Pharmaceuticals Inc. \u2013 NASDAQ:XENE", "summary": "This article focuses on the enterprise value to EBIT forward for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). It appears to be a financial data point or a report generated by TradingView, a financial platform. The content primarily lists navigation and footer information related to", "url": "https://www.tradingview.com/symbols/NASDAQ-XENE/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T12:10:27", "published_display": "01 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (XENE) That Institutions Follow", "summary": "This article analyzes Xenon Pharmaceuticals Inc. (NASDAQ: XENE) using AI models to identify institutional trading signals. It highlights strong sentiment across all horizons, an exceptional risk-reward setup, and provides three distinct trading strategies: a Position Trading Stra", "url": "https://news.stocktradersdaily.com/news_release/141/The_Technical_Signals_Behind_XENE_That_Institutions_Follow_062926093801_1782783481.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T21:38:00", "published_display": "29 Jun 2026 21:38", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Positive X-TOLE2 Epilepsy Data And 2026 FDA Filing Plan Altering The Investment Case For Xenon Pharmaceuticals (XENE)?", "summary": "Xenon Pharmaceuticals recently announced positive Phase III X-TOLE2 results for azetukalner in focal onset seizures and plans to submit a new drug application to the FDA for this indication in Q3 2026. This progress advances azetukalner within the company's neuroscience pipeline ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/is-positive-x-tole2-epilepsy-data-and-2026-fda-filing-plan-a/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-24T13:41:15", "published_display": "24 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why", "summary": "Xenon Pharmaceuticals (XENE) stock has surged 22% over the past six months, outperforming the industry's decline, driven by strong investor confidence in its neuroscience pipeline. Key to this growth is azetukalner, the company's lead asset, which showed positive phase III result", "url": "https://finance.yahoo.com/markets/stocks/articles/xenon-pharmaceuticals-stock-gains-22-145900961.html", "source_name": "Market source", "published_at": "2026-06-23T17:11:13", "published_display": "23 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals (XENE) Q4 2025 earnings summary", "summary": "Xenon Pharmaceuticals released its Q4 2025 earnings, highlighting significant progress in Phase 3 clinical trials for azetukalner in epilepsy and neuropsychiatry, with NDA submission expected in 2026. The company expanded its early-stage pipeline and raised $242.2 million through", "url": "https://quartr.com/events/xenon-pharmaceuticals-xene-q4-2025_oqhcq8m4", "source_name": "Quartr", "published_at": "2026-06-23T04:40:32", "published_display": "23 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc (XENE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for Xenon Pharmaceuticals Inc (XENE), including its stock performance, market capitalization, and financial overview. It notes that relevant data regarding business segments, regional revenue, and profit contribution for recent fiscal year", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xene/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:24", "published_display": "18 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc (XENE) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Xenon Pharmaceuticals Inc (XENE), including its major shareholders and institutional holdings. It lists the top individual shareholders like Fidelity Management & Research Company LLC and Avoro Capital Advisors LLC, as well as cat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xene/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:24", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc (XENE) Institutional Confidence", "summary": "Xenon Pharmaceuticals Inc (XENE) has an institutional confidence score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 116.66%, a 21.96% increase quarter-over-quarter. Paul Tudor Jones is the largest institution", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xene/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T08:41:26", "published_display": "17 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc (XENE) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Xenon Pharmaceuticals Inc (XENE), highlighting its current earnings forecast score, analyst ratings, and price targets. It includes a peer comparison and addresses frequently asked questions regarding expected revenue, price targets,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xene/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T08:41:25", "published_display": "17 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate", "summary": "Xenon Pharmaceuticals (XENE) recently experienced a share price pullback, with the stock down around 3% in the past day and 4% in the last week, yet it has shown strong performance over the past year. Despite the recent dip, Simply Wall St assesses XENE as modestly undervalued at", "url": "https://sg.finance.yahoo.com/news/assessing-xenon-pharmaceuticals-xene-valuation-171159398.html", "source_name": "Market source", "published_at": "2026-06-11T17:39:02", "published_display": "11 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE", "summary": "Fiera Capital Corp increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 31.9% in the fourth quarter, bringing its total holdings to 686,056 shares valued at $30.7 million. Several other institutional investors also increased their positions, indicating significant i", "url": "https://www.marketbeat.com/instant-alerts/filing-fiera-capital-corp-boosts-stock-position-in-xenon-pharmaceuticals-inc-xene-2026-06-09/", "source_name": "MarketBeat", "published_at": "2026-06-09T23:39:02", "published_display": "09 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade", "summary": "Xenon Pharmaceuticals director Gary Patou sold 1,322 shares of XENE stock at $53.14 per share on June 5, 2026. This transaction was conducted under a pre-planned Rule 10b5-1 trading plan adopted in August 2025, specifically to cover income tax obligations from the vesting of rest", "url": "https://www.stocktitan.net/sec-filings/XENE/form-4-xenon-pharmaceuticals-inc-insider-trading-activity-65e1bc7cd4e9.html", "source_name": "Stock Titan", "published_at": "2026-06-09T01:39:02", "published_display": "09 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals (XENE) director Cannon sells 1,190 shares under 10b5-1 tax plan", "summary": "Xenon Pharmaceuticals Inc. director Gillian Cannon sold 1,190 common shares at an average price of $53.14 per share on June 5, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, primarily to cover income tax obligations from", "url": "https://www.stocktitan.net/sec-filings/XENE/form-4-xenon-pharmaceuticals-inc-insider-trading-activity-1157e4216298.html", "source_name": "Stock Titan", "published_at": "2026-06-09T01:39:02", "published_display": "09 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Xenon Pharmaceuticals Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Xenon Pharmaceuticals Inc. (XENE), detailing a proposed sale of 1,322 common shares by an insider. The filing indicates the securities were acquired on May 31, 2026, as Restricted Stock Units from the issuer. The aggregated market ", "url": "https://www.stocktitan.net/sec-filings/XENE/144-xenon-pharmaceuticals-inc-sec-filing-cd3da1332bcf.html", "source_name": "Stock Titan", "published_at": "2026-06-07T12:39:44", "published_display": "07 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Xenon Pharmaceuticals (XENE) Valuation After A Recent Pullback And Strong Multi Year Returns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc. Rings the Nasdaq Stock Market Opening Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOZ29fd3dUUFdEZHg2Yk8xTi11SlBoeWItTTQtYWpwSV96dVJfZzNERDEyaDBWMHNra1hsZmd5ZWtIMm0wWE53Nk1KVzhJNmhfZjBDalhQWW4zLV93NDI3aS1KU094S1RLT3ZabmJIUXFCbDE5c0J1Z2tzMVBWMEl3UUpjcXpndWJwaUt3aXpDbXhXSkptOVZFSll3?oc=5", "source_name": "Nasdaq", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOaEpJcU5wUXFpM0Q4RHJVWnRIWTdacjFUd1JqbU14clloakhGUUN2SXdUTXdoUmJtVjJFNVNSV2hVRXE1azAwWUQ0QmNQTHJ3OWJKenNSUTFBTzZLZVNPMmtPTnZCY2N2M2JBZ3lzSjZVX2M4VkhnYm94dE54NVFHaDNwSWhOMmVwTE50MkVrWG5FVDNOZV9QT2UzdTVZdEl3?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This Fund\u2019s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPQUFrTnM0c0MxSHNXYm9RUHBwMVpYNzlMdzJ4Q1NoM003c1MzeDFQWVh0UGpwZHdOSTlqbGxLcjl3ZUFWdVcycmdvRDc3aUFMYk1XazBSNEs0ZnRDamVRODEzajlVZ2pGVXdZdWZ4em16cHlPb0VaT0FQNkNZWFdTeHNFUG1aLWloRkowdGpTdW1sUUdQc0ZrcENzTGdtV2ZlTGticUJPa1VnR2xTVzJYeS1qZ2VpTE1jM1V1NHY3TEVycnJ3TDM1YkZFREhIbzhOcF95S1VaMjR1S1NXZ1pPMQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOV0E1T0hTcGZEMHZ4RVM0Smx2Z3Jic2xaS1YzcWVSNGh1Vll0ckMyaDB4YUFpcnRQeTQwWDlkTHRKMHp5T1hLeHNYSG1XbHF2RXJjUVlGVmlLU3ZUZ3U3c0xDTDhYaHlvZlc4ekY2cjJ1aE9FejY4MWxRZ2twenFrTmNNYVBvMDk4d09QVzFwV3FzTUY5?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOcWJGU3RuSkViYm1wVW8yV3NfaHBWa214X0MwRDRRVDBlRTFUbkgyemYzakdZZVQzM0tTdWJIVjhOYm1OaVJGR1FNZGxBV3JTR1RPQno1LWkwX1FGbFRvSVFKaUJzTGQyQlN1OGQ3dEcwdklFMGttRlp6bHgxenV1U0huaDUzbmNMdkQ1dkdCMXNHZGxpMXhkanZuUkRocUVPTVE0RjY4SWtaNnAwaDBn?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNZWxCSGkwTjRJQUttYVVmeGdsRDBOanozWl9LZWxqQTR0VHlzLVBNVEZjWkxVMXFrTVpPNkpWTjQ2NWlYTnRMODZGWXNvX0tEcWp2cDdNaUtjZ0RzbU8xMFBya1hFa1ZZNUhvS0hmc2gxVFhsVzFPWlY2c0FhMllpTWRSdjU0T0thclBjZzlJYTA2UzF4VW5NUzNvVXpUa08zUlktSXFrMXVQOXRqNkFxcDFmTG1ORmpEUWJ1UFNuWkZtOGd2N2I5bXdiN2R4Vm8?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Xenon Pharmaceuticals (XENE) After A 58% One-Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNZDZ0YkZyOVpPWlhWYzlJS3FZdHd6VlB2ZDRfYUJEWGZQb2xZMGxzUENwQ1RXMFc4aDJHRnA3MkhKS1ZpMUtvVlljSFVjbkh4NXBTRlBJSl95TFBJQl8zU0VFTXhXeVBLNlE1SGpRV2puR2VGa0JVTDF2Ty1PeEh0RU1rdm11SWtQVlhCRGhEclFQMC1UWHU1YjFTcjc4cTJYRkZJLThuZUZxVC1IOGhSVklCek8xZVhjQ3Z4TzlDeHhFUFpyVjIxU3A1VVJIeE0yR0MtYWRFLWpCOWZmRHVnSXlPWDNMQnVKZXfSAe8BQVVfeXFMT29QSTA2X19iYklOSnRob0NpdG5xcWFPS1VBdG1SQ0U3d2kwTEVLT0k5bkE0M1k2dktPeE1tYzFYbGtpcW1UZDM2cXc3M1F2Z3dwZ3Nzb0NpMF9jODF3dHJXUTBWa0dJZHBsZmRjcnZXamppVVEyU0kwQms3alhMMFRncXFzOEluVUY0QndoSFdXamZ6VmRlNFBvT1BzbnhWTUNRQWNBTm9malJOLU1NQnIwUk5hUDlON2dSNVdIQUsxdFFyWVQwOEU2UjNrRzh2ZkVCTDdnVllKVEw4OS1SYi12aVJEN1hjVTYxYVh6U28?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nearly 40% stayed seizure-free for a year in Xenon\u2019s 48-month study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPckRHRjZqWlBJZGw2Mms3eTA3QTFTUXczUlZ6d3Y2R2d3SjVia25Pb09ZLXQ1VnN4OUpxamFCYTMtem56Q29DY3B5aVRoTGlpVjBPQk10SS1yYjBPZi1YdmkwcFlQOTRTWmhBSkFRdzNxT0Q2dDcxT0V6WVpTcTZpM2ZJM055eThQSmdBQlRFUHA1LUg3am91MXRNWkdCSnpSbDM2ZnpkRm40NGxHbkFackhXRGdieTNyU2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon lines up four investor conference presentations in Q2 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQNDNvNDNxMFNjT0s1bWo4TWZtdWY1aWNFdjNRYUo3a2NaUnNieEdPWTBoUF9JX1pFdjhMYzJBeXpZZVhENmxwak1ISGlKM3lEcFlNcXlRdFpOc2xweGtwdmY2NTlpM0xPbGRsVjNUOVVYUFdqWC1ra2xsaGRmZ1R0RE9nbXd5bmdEaEI4T0NVdHY2akVfOEh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPalF4RnBqQlU5MEp5MWtma21jdnN5ZFJNZ0tMUmtScTF6VEtDXzJGQ0kxbHdNT1dmSHlNczlnMHoyVjNSV2hGMWNPMjVqbF84cktDcnJPRElmdVluQXdaQkZqOU4yekhqRmlmVFZUeVBVMHJjZExHVUY1aEJmamtlTnhiT1ZGeGl3bVlpekNWckxJcmt5NF9jUmVGQk15S0ZlbUtLMGNqZWktaGY1NlY3Y2VVa1ZUNGY1eDFodmhURUVHNzNKMFNucXdkNEMybVZOM2VKM2VWTFpDUQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNM3o0VWhQY2FBaWtuMWFlTU9aZmc3alB2VWU5S0ZnZGx5UFFMRXhUYzZpVnRkV28zeGJYcVRNQWk4RU9sNllCMmk0ZktyNkstcEpWNTFSNUhmVkhsRlFzODhTY0xHY0F2bXc1S1UxQlZFWTgxUnpGamNnbEJaeTZEdUhqMVRmYXlNeXBlY1d2ZFdsRHlUaGlLTHVKTXR4NFZjcUM4?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals (XENE) Is Down 6.7% After $650 Million Follow-On Offering And Phase 3 Epilepsy Win", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOSFpmdkYzaWotWGJMb0lleVVGY0lZOVRpMlhPbFc3RGdUTmpOYzF4czBqcmxkc1VvZUNCUFFqX0ZfTjM3WllwNWE0ZjEtb2ZoWXhPY0pONUhUWE8yZlFYVkU4ODFGWWhMbG1paHprZVJxazVzSnhualFZNlJobDZhMXBWeTJreUh1UU01TVJiZXNyWm00NWVZTktxSWRwR2M?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Do Recent Insider Sales at Xenon Pharmaceuticals Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNR3VQZlVLYk1rNi1fZWcyZDQ0ZlBZWjRtLW5KbFYtMFl4NmhzZ1lXZlgyMFd4YlZfOW1ycHFwZTBpTUZaOXpGeVNmTzU2SUhPZ2p2bVp0S0tMMWNTWFNqMkJwVm1KM1lZLTd3SUp2S1pQbmwyQ3FWd1JsX1EteUZiSUt1Y0VzbDE5SkNFMW9oeC13cnhZMFFZbXdINA?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals Inc. Prices Upsized Public Offering, Anticipated Gross Proceeds of Approximately $650 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQYl9MbVRILVlFaUNGSmY2M2JTd3BXVkZ6dmYzN1Q1VzNxWWFFUzM0cmJqN1pWYlp6YndmekJlMy1peXo5aWd6amhjOHlXdkdwYXhzY1pmNGotUmRqRVNVT2JMV0tqQXpVaXVVTVVqM1IzVGxJbTVCb2hYTXY5X2dnSXlCYjh1dmRMNWxuT2F0QlVsbHVMempFclItLVpQMV9OSlFicDZ0M2hfMmZHZDM2aWRIUFBLVVY1R240cnp0VGJWSlJZUmpvVjRXV0JLVkZ1OHUyVlViVTZpam1QcmlsUDBkMVdCeTg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Xenon raises $650M in stock sale at $57 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOWjFPVUI3R1pOSWMxUHM4aHRvUUZkV3U5b05UbHZSZ3ljdGNjNjBxYXhiQklNTHlKM3FfMEN6dGRmMUJOT2R2UlJYTFZRZTZLOC1YT2xzOWNDWEdzZ0tEWkxTN3NFTktSV19oTHRLVFlTTnVSSWs0cXlOQk1QekVzSmg0LVhvNnZ0bzd0LVVmbDRwX2M0a2hrMHUydEhGcWY2bHVWbFVMeGp0eUpkX1A4SXJMZjVRbmpORTVJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals surges 43.6% as Phase 3 azetukalner epilepsy data beats expectations | XENE Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPTW8zQkt6RXBZcUVNZEc1SVRVUkFxV3FKeVU0eldZVzFJMS1WQ0I1UGJ6a2wzcUFTV05Ubmx5V2d6UlBWQk1UV0tDTzVzVWdWMEZyNlZUWV9ZU0xDcnFhTlJDTWJDeURxVlpFTEFZZHU5MnlCOExFUFZUN2V1eXZDZHEwd00tUGRSU1AyY2tlY0VGT1gzVFJ5cFAxUGU5TE1HM1JxNVEzVlJXdUc4Y1BCZkxvOXpWaENfSDQ4RHNuQnp2UjQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals stock surges 40% on positive trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNcDhRNkNoQlAxcEZWRWhIOHJJNFU5UjVPQUFZREdVdjhKYi1WSmprakZlOEFjYjRTQVRoU04xVmtqUnFTU0dmRFp5cElBbDV0Q091QzFvLVE5MktCMVFORWFRaVRlcWxJVE4yRmp2SHVBOWZObVU2UTFVc1dNUFh4UDBPNno3R1RobFdkSjBpbFVjTEI4ZFdmVVRxQ0VaN3lYTVdmSG1OVXgxRnFrbUItTi1TMW9QN1VsOG9hZjRWQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: Chevron, Hims and Hers, Xenon Pharma, Vertiv and more", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPMmZWSnNMTWNIU2RQZXBTY1NyV0J2TFVHaUJQWjhMdHVUZXNnTVFMNTNPdXV1Z0JVU0hLejUxcWlwWmpBbEFBQXY4aGdlaFNnY1N0ZHBSZUZSWVVhM21wMThCRW40bkU3dGZPdV9LSXJMMzh1ZDB3WmFSS2NSaUVNZnlEdnFKY2ZhS2JuN3IzQXV2bE9hWVJPZ1lrZ2ZIZGJU?oc=5", "source_name": "CNBC", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdWFjSms4YllueTRzeGVIUnM5anp4N0dDNVRJbU9aSTFNb21uVEpTc19jRTJyYTRrLVVPNXNfcGwzdTlfWTBtV3c3SUFncFZraXpwX3FaSU9pTi1QdFB4VktTeWlab1MzTnBpeGFaNVgzYktSR05hUHFQeHI5dWtkS2JpY1Zob3VyeEYwMXlmdXlwUkpMenlhaE9CVGRDaWd5eC02TWQ2cXVNWU85bHR6SS1ENXFUYjJmLTZz?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 55, "sentiment_summary": {"positive": 20, "negative": 1, "neutral": 34, "score": 58, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 17.2, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 9.35, "count": 19}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}], "positive_events": 20, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 68.92, "latest_week": "2026-07-10", "one_week_move": 13.1, "four_week_move": 32.3, "twelve_week_move": 15.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.072606, "market_dynamics_buy_signal": false, "relative_strength": 30.416069, "fair_value_gap": 67.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.5931, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+13.1% over one week, +32.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 19}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+13.1% over one week, +32.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds"}], "updated_at": "2026-07-16T08:11:37.713498+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}